UNITED ~~STATESSECURITIES~~STATES SECURITIES AND EXCHANGE ~~COMMISSIONWASHINGTON~~COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11 22, 2026

Definium Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

British Columbia	001-40360	98-1582438
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
One World Trade CenterSuite 8500
One World Trade Center Suite 8500
New York, New York		10007
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (212) 220-6633

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class ~~TradingSymbol~~Trading Symbol(s) Name of each exchange on which registered Common Shares DFTX The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐¨

Item 57.0201 ~~Departure~~Regulation ofFD ~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Disclosure.

~~Approval~~On June 22, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing positive topline data from the Company’s Phase 3 Emerge study of ~~Amendment~~DT120 toODT for the ~~Definium~~treatment ~~Therapeutics,~~of ~~Inc~~major depressive disorder. ~~2025~~A ~~Equity~~copy ~~Incentive~~of ~~Plan~~the Press Release is furnished as Exhibit 99.1 hereto, and is incorporated by reference into this Item 7.01.

AsThe ~~described~~information infurnished pursuant to this Item 57.~~07 below~~01, onincluding ~~June 11~~Exhibit 99.1, ~~2026,~~shall ~~Definium~~not ~~Therapeutics,~~be ~~Inc.~~deemed ~~(the~~to be “~~Company~~filed”) ~~held~~for ~~its~~purposes ~~2026~~of ~~Annual~~Section 18 ~~General~~of ~~and~~the ~~Special~~Securities ~~Meeting~~Exchange Act of 1934, ~~Shareholders~~as amended (the “~~Annual~~Exchange ~~Meeting~~Act”)., Ator ~~the~~otherwise ~~Annual~~subject ~~Meeting,~~to the ~~Company’s~~liabilities ~~shareholders~~of ~~approved~~that anSection, ~~amendment~~nor shall it be deemed to be incorporated by reference into any of the Company’s ~~2025~~filings ~~Equity~~with ~~Incentive~~the ~~Plan~~SEC tounder ~~increase~~ the ~~number~~Exchange ofAct or the ~~Company's~~Securities ~~common~~Act ~~shares~~of 1933, as noamended, ~~par~~whether ~~value~~made ~~(“Common~~before ~~Shares”)~~or after the date hereof, ~~available~~regardless ~~for~~of ~~issuance~~any ~~thereunder~~general byincorporation 5language in such a filing,~~000,000~~ ~~Common~~except ~~Shares~~as expressly ~~(the~~set ~~“Equity~~forth ~~Plan~~by ~~Amendment”)~~specific reference in such a filing.

~~The~~Item ~~Company’s Board of Directors previously approved the Equity Plan Amendment on April 6, 2026, subject to shareholder approval at the Annual Meeting~~8.01 ~~The~~Other ~~Equity Plan Amendment became effective at the time of shareholder approval~~Events.

AOn ~~summary~~June 22, of2026, the ~~material terms of the~~ Company’s ~~2025~~posted ~~Equity~~a ~~Incentive~~presentation ~~Plan and~~ discussing the ~~Equity~~Emerge ~~Plan~~topline ~~Amendment~~data ~~is set forth in~~ (the ~~Company’s~~“Presentation”) ~~Definitive Proxy Statement~~ on ~~Schedule~~its ~~14A for the Annual Meeting, filed with the Securities and Exchange Commission on April 27, 2026 and is incorporated by reference into this Item 5~~website.~~02.~~ ~~Such~~A ~~information~~copy ~~and the foregoing description~~ of the ~~Equity~~Presentation ~~Plan Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the Equity Plan Amendment, a copy of which~~ is ~~attached~~filed ~~to this Current Report on Form 8-K~~ as Exhibit 10 99.12 hereto, and is incorporated by reference into this Item 58.0201.

Item 59.0701 ~~Submission~~Financial ofStatements ~~Matters~~and ~~to a Vote of Security Holders~~Exhibits.

~~On June 11, 2026, the Company held its Annual Meeting~~(d) Exhibits. As of April 15, 2026, the record date for the Annual Meeting, 109,066,783 Common Shares were outstanding and entitled to vote at the Annual Meeting. A quorum was present at the Annual Meeting under the Company’s amended and restated articles, and there were 78,673,592 Common Shares present or represented at the Annual Meeting by valid proxies representing approximately 72% of the Common Shares entitled to vote at the Annual Meeting. The Company’s shareholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in the Company’s Proxy Statement.

Set forth below are the final voting results for the Annual Meeting as certified by the Independent Scrutineer of Elections on June 11, 2026, as well as a description of the proposals voted on at the Annual Meeting.

Exhibit No.		Description
99.1		Press Release, dated June 22, 2026
99.2		Emerge Topline Data Presentation, dated June 22, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

~~Proposal 1 – Election of Directors~~ SIGNATURES

~~The~~Pursuant ~~Company’s seven nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone, and Roger Adsett, were each elected~~ to ~~serve~~the asrequirements ~~a member~~ of the ~~Board~~Securities ~~until~~Exchange ~~the~~Act ~~2027 annual general meeting~~ of ~~shareholders (~~1934, the ~~“2027~~registrant ~~Annual~~has ~~Meeting”)~~duly orcaused ~~until~~this areport ~~successor~~to ~~has~~be ~~been~~signed ~~duly~~on ~~elected~~its orbehalf ~~appointed,~~ by the ~~following~~undersigned ~~votes:~~ hereunto duly authorized.

Company Board Nominee		Votes For		VotesWithheld	Broker Non-Votes
			DEFINIUM THERAPEUTICS, INC.
Robert Barrow		62,881,122		173,376	15,619,094
Date:	June 22, 2026	By:	/s/ Robert Barrow
Dr. Suzanne Bruhn		62,503,873		550,625	15,619,094
			Name: Robert Barrow
Dr. Roger Crystal		60,056,178		2,998,320	15,619,094
			Title: Chief Executive Officer
David Gryska		62,760,423		294,075	15,619,094
Andreas Krebs		62,395,043		659,455	15,619,094
Carol A. Vallone		62,623,945		430,553	15,619,094
Roger Adsett		62,931,294		123,204	15,619,094

Proposal 2 – Appointment of Auditor

The shareholders approved the appointment of KPMG LLP as the independent registered public accounting firm (auditor) of the Company until the 2027 Annual Meeting by the following votes:

Votes For		Votes Withheld		Broker Non-Votes
78,579,054		94,538		-

Proposal 3 – Approval of the Equity Plan Amendment

The shareholders approved the Equity Plan Amendment by the following votes:

Votes For		Votes Against		Votes Abstain		Broker Non-Votes
58,149,028		4,708,102		197,368		15,619,094

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
10.1		Amendment No. 1 to Definium Therapeutics, Inc. 2025 Equity Incentive Plan
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			DEFINIUM THERAPEUTICS, INC.
Date:	June 12, 2026	By:	/s/ Robert Barrow
			Name: Robert BarrowTitle: Chief Executive Officer

Filing Compare · Definium Therapeutics, Inc.